Ipodate sodium

Ipodate sodium

Clinical data
Trade names	Oragrafin
Routes of administration	oral, Intravenous
ATC code	V08AC08 (WHO)
Identifiers
IUPAC name sodium 3-(3-{[(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoate
CAS Number	5587-89-3
PubChem CID	14651
ChemSpider	13984
UNII	F604ZKI910
ChEMBL	ChEMBL1201033
CompTox Dashboard (EPA)	DTXSID9048271
ECHA InfoCard	100.013.587
Chemical and physical data
Formula	C12H12I3N2NaO2
Molar mass	619.943 g·mol−1
3D model (JSmol)	Interactive image
Melting point	168–169 °C (334–336 °F)
SMILES CN(C)/C=N/c1c(cc(c(c1I)CCC(=O)[O-])I)I.[Na+]
InChI InChI=1S/C12H13I3N2O2.Na/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h5-6H,3-4H2,1-2H3,(H,18,19);/q;+1/p-1/b16-6+; Key:ZFHZUGUCWJVEQC-FPUQOWELSA-M

Ipodate sodium (sodium iopodate) is an iodine-containing radiopaque contrast media used for X-rays. The drug is given orally and the resulting contrast allows for easy resolution of the bile duct and gall bladder.

Although not FDA approved, ipodate sodium has been used to treat Graves' disease and thyroid storm, an extreme form of hyperthyroidism.

Long-term treatment of Graves' disease with ipodate sodium (500 mg, daily) given by mouth reduced levels of T3 and T4 in the patients.^[1] This was done with minimal side effects, indicating possible clinical usefulness. Iodine uptake was also noted to return to normal within seven days, indicating control with ipodate with rapid follow up treatment with ¹³¹I is feasible.

In emergency situations, ipodate can be administered for thyroid storm. As the ipodate is metabolized, it releases iodine into circulation, helping bring the T3 and T4 levels back down. Ipodate also inhibits the conversion of T4 to T3 (which is more potent). It is not considered a first-line approach, as potassium iodide and beta blockers have less potential for side-effects. Ipodate sodium lacks FDA approval for this use.